Amgen acquires BioVex

Amgen has agreed to buy BioVex, a closely held maker of experimental cancer drugs, for up to $1bn (£633m). An initial payment of $425m will be made, and as much as $575m in milestone payments. Biovex is a privately held, venture-funded, biotechnology company headquartered in Woburn, Massachusetts.